Related Experiment Video
Updated: Oct 5, 2025
03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
552
Decreased E2F2 Expression Correlates with Poor Prognosis and Immune Infiltrates in Patients with Colorectal Cancer
Yuanyuan Shang1, Yuanyuan Zhang1, Jie Liu1
1Department of Colorectal Surgery, Department of General Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Journal of Cancer
|January 24, 2022
Summary
Transcription factor E2F2 is downregulated in colorectal cancer (CRC), correlating with poor prognosis and immune infiltration. This suggests E2F2 may serve as a diagnostic biomarker and therapeutic target for CRC patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The role of E2F2 (transcription factor E2F2) in colorectal cancer (CRC) tumorigenesis is not well understood.
- Existing evidence suggests E2F2 involvement in various cancers.
Purpose of the Study:
- To investigate the expression, prognostic value, and functional role of E2F2 in colorectal cancer.
- To determine if E2F2 can serve as a diagnostic biomarker or therapeutic target for CRC.
Main Methods:
- Bioinformatic analysis using TIMER, Oncomine, TCGA, GEO, and PrognoScan databases.
- Experimental validation via immunohistochemistry, qRT-PCR, and western blot on CRC tissues.
- Functional analysis using Gene Set Enrichment Analysis (GSEA) and immune infiltration analysis.
Main Results:
- E2F2 expression is significantly downregulated in CRC tissues compared to normal controls.
- Low E2F2 expression correlates with advanced pathological stage (N, M stages) and poor overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), and progression-free interval (PFI).
- E2F2 is implicated in DNA repair pathways, cancer stemness, and is associated with specific immune cell infiltrations (Th2, aDC, Th17, NK CD56dim, T helper, pDC).
Conclusions:
- Decreased E2F2 expression is a significant indicator of poor prognosis in colorectal cancer.
- E2F2 shows potential as an independent prognostic biomarker and a therapeutic target for CRC.
- E2F2's association with immune infiltration highlights its role in the tumor microenvironment.
Keywords:
E2F2bioinformatics analysiscolorectal cancerimmune infiltrationimmunohistochemistryprognosisMore Related Videos
Related Concept Videos
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.3K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.3K
02:07Tumor Progression
6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K